

PRESS RELEASE

SVAS BIOSANA COMPLETES TRANSACTION TO ACQUIRE THE "BORMIA" GROUP

Somma Vesuviana (NA) 23 June 2022 – Following the previous announcement of 17 May 2022, Svas Biosana S.p.A. ("Company" or "SVAS") disclosed that the transaction to acquire 75% of the share capital of Bormia d.o.o. ("Bormia") was closed today ("Closing Date"). Listed on the Euronext Growth Milan market, SVAS is a leading operator in the healthcare sector that produces and distributes medical devices for public and private healthcare facilities. Bormia is a company that distributes specialised medical devices to primary public and private customers of the Slovenian, Croatian, Serbian and Bosnian healthcare system. Bormia will continue to hold the remaining 25% of its stock.

With the acquisition of 75% of Bormia, which was completed through its subsidiary Levante HC Holding, SVAS Biosana not only retains its leadership role in the supply of medical devices in the Balkans, but also further strengthens its competitive position in the area.

According to **Umberto Perillo, CEO of Svas Biosana S.p.A.:** "Just six months after SVAS' listing we are pleased to have closed the acquisition of 75% of Bormia. With the closing of the transaction, today we took an important step forward in the specialised medical devices market in Eastern Europe, which will see us as the leader in this sector and in these countries for the years to come. Our organisation in the Balkan area continues to grow and develop also thanks to the contribution of a management already strong and qualified in the area".

Boris Cotic, Director of Bormia, stated: "I am very proud of the work done and I want to thank all the employees who with their dedication and professionalism contributed to make Bormia become a successful, reliable and, above all, respectable distributor of medical devices. It is with great enthusiasm that we will work with SVAS in developing medical devices in Eastern Europe, braving the challenges of the years to come together and aware that we belong to a listed Group of high standing with growth and development ambitions".

The Bormia Group, which is not required to prepare consolidated financial statements and operates in Slovenia through Bormia d.o.o. and in Croatia through its subsidiary Bormiamed d.o.o., recorded the following pro forma consolidated figures at 31 December 2021, not subjected to audit:

- Revenues: Euro 11.0 million, up by 26.4% on 2020
- EBITDA: Euro 1.25 million, up by 11% on 2020

Companies Register of Naples no. 4543/85 Economic and Tax Code 04720630633 VAT no. 01354901215 Via M. Perillo, 34 80047 San Giuseppe Vesuviano (NA) Post Box 91 80049 Somma Vesuviana (NA) Italy

80049 Somma Vesuviana (NA) Italy

Contacts



EBITDA margin: 11.4%

Net profit: Euro 889 thousand, up by 9.3% on 2020

Net profit margin: 8.1%

Cash positive NFP of approximately Euro 965 thousand

20 employees

Additional information about the acquisition

The transaction consisted in the transfer of 75% of the relevant share capital of Bormia d.o.o. to Levante HC Holding through 3 capital shares by the current shareholders Maja Vecerina, Igor Bogatec and Boris Cotic, ("Sellers") for a total final amount of Euro 4.80 million, paid in full by Levante upon closing, while Bormia will continue to hold 25% of its own capital shares in its portfolio.

The acquisition, worth a total of Euro 4.8 million, was financed entirely using own funds, through Levante HC Holding D.o.o., wholly-owned by Svas Biosana S.p.A.

* * * * * * *

This press release can be found at Borsa Italiana, at the Company's registered office, and in the *Financial Releases* section of the company's website www.svas.it.

Svas Biosana uses the eMarket SDIR system, managed by Spafid Connect S.p.A., with registered office at Foro Buonaparte 10, Milan (www.emarketstorage.com), to disclose regulated information.



Contacts:

SVAS Biosana S.p.A.

Andrea Efficace
CFO Group and Investor Relations Manager
+39 081.8995411
a.efficace@svas.it

Investor Relations Advisor

POLYTEMS HIR Bianca FERSINI MASTELLONI - Silvia MARONGIU 06.69923324-066797849 s.marongiu@polytemshir.it

Specialist

Banca Profilo +39 02.584081 **Euronext Growth Advisor**

Banca Profilo
Via Cerva 28, Milan
+39 02.584081
alessio.muretti@bancaprofilo.it

Media Relations Advisor

POLYTEMS HIR
Paolo SANTAGOSTINO
+393493856585
p.santagostino@polytemshir.it

Svas Biosana manufactures and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international company with a catalogue of approximately 16,000 own and third party brand products, roughly 370 employees, a Research and Development department, 3 production facilities in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia-Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157